

RESEARCH

Open Access



Effects of *Atractylodes lancea* extracts on intestinal flora and serum metabolites in mice with intestinal dysbacteriosis

BaiNian Zhang^{1†}, Lan Bu^{1†}, Hui Tian^{1*}, ZhangQiang You¹, MingHai Zhao¹, Jie Tian¹, YuanYuan Zhang¹, Qian Wang¹, ChengJia Tan¹, Yu Cao, DaRen Feng² and ZhenPeng Xi³

Abstract

Objective This study aims to explore the effect of an extract of *Atractylodes lancea* (*A. lancea*) on antibiotics-induced intestinal tract disorder and the probable therapeutic mechanisms employed by this extract to ameliorate these disorders.

Methods Three days after acclimatization, nine male and nine female specific-pathogen-free (SPF) mice were randomly assigned into three groups: Group C (normal saline), Group M (antibiotic: cefradine + gentamicin), and Group T (antibiotic + *A. lancea* extract). Each mouse in Groups M and T received intragastric (i.g.) gavage antibiotics containing cefradine and gentamicin sulfate (0.02 ml/g⁻¹/D⁻¹) for 7 days. *A. lancea* extract (0.02 ml/g⁻¹/D⁻¹) was administered by i.g. gavage to Group T mice for 7 days following the cessation of antibiotic therapy. Group M received an equivalent volume of normal saline for 7 days, while Group C received an equivalent volume of normal saline for 14 days. Afterwards, we collected mouse feces to assess changes in intestinal microbiota by 16S ribosomal ribonucleic acid (rRNA) sequencing and metabolomics. In addition, serum samples were gathered and analyzed using liquid chromatography–mass spectrometry (LS-MS). Finally, we performed a correlation analysis between intestinal microbiota and metabolites.

Results After treatment with antibiotic, the richness and diversity of the flora, numbers of wall-breaking bacteria and Bacteroidetes, and the numbers of beneficial bacteria decreased, while the numbers of harmful bacteria increased. After i.g. administration of *A. lancea* extract, the imbalance of microbial flora began to recover. Antibiotics primarily influence the metabolism of lipids, steroids, peptides, organic acids, and carbohydrates, with lipid compounds ranking first. Arachidonic acid (AA), arginine, and proline have relatively strong effects on the metabolisms of antibiotic-stressed mice. Our findings revealed that *A. lancea* extract might restore the metabolism of AA and L-methionine. The content of differential metabolites detected in the serum of Group T mice was comparable to that in the serum of

[†]BaiNian Zhang and Lan Bu are contributed equally to this work.

The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive (Genomics, Proteomics & Bioinformatics 2021) in National Genomics Data Center (Nucleic Acids Res 2022), China National Center for Bioinformation/Beijing Institute of Genomics, Chinese Academy of Sciences (GSA: CRA010165) that are publicly accessible at <https://ngdc.cncb.ac.cn/gsa>.

*Correspondence:

Hui Tian

tianhui1009@126.com

Full list of author information is available at the end of the article



Group C mice, but significantly different from that of Group M mice. Compared to putative biomarkers in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, it was found that altered metabolites, such as amino acids, glycerol, and phospholipids, were primarily associated with the metabolism.

Conclusions The effective mechanisms of *A. lancea* extract in regulating the disorder of intestinal flora in mice are related to the mechanisms of *A. lancea*. It could relate to lipid metabolism, bile acid metabolism, and amino acid metabolism. These results will provide a basis for further explaining the mechanism by which *A. lancea* regulates intestinal flora.

Keywords *Atractylodes lancea* extract, Gut microbiota, Metabolomics

Introduction

The gut microbiome is an essential microecosystem for the host's health and metabolic equilibrium [1]. It is crucial to maintain the microenvironmental balance of the gut microbiota [2]. When the balance is disrupted by external factors such as food poisoning [3, 4] and antibiotic abuse [5–8], the host's intestinal flora is disturbed and metabolic level and health are impacted, resulting in decreased immune function, impaired internal organs and bone marrow hematopoietic function, leading to anemia and other diseases. In recent years, numerous studies have demonstrated that traditional Chinese medicine (TCM) can stimulate the proliferation of probiotics, limit the growth of harmful pathogenic, and preserve the gut microbiota's balance [9].

Atractylodes Rhizoma is a perennial herb of the family Compositae [10]. There are around seven species in the genus *Atractylodes*, which are primarily found in eastern Asia. There are five species in China, such as *A. lancea*, *A. macrocephala*, *A. carlinoides*, *A. koreana*, and *A. japonica*. The dried rhizomes of *Atractylodes lancea* or *Atractylodes chinensis* are referred to as *Atractylodes Rhizoma* in the 2020 edition of the Chinese Pharmacopoeia. This substance is widely available throughout China. Several *Atractylodes* species are utilized instead of *A. carlinoides* for clinical therapeutic uses. This article uses *A. lancea* [11] exerting various pharmacological effects, which are applied widely in clinical practice, such as treating gastric ulcers [12–15], tumors, and inflammation [16], protecting the liver [17], regulating gastrointestinal (GI) activities [18], and inhibiting gastric acid secretion. It is particularly effective in the treatment of GI diseases. Researches on its pharmacological action in treating various disorders have been conducted at home and abroad [19]. However, there are very few investigations on the mechanism by which *A. lancea* heals gastrointestinal diseases.

Combining 16S ribosomal ribonucleic acid (rRNA) microbial-diversity sequencing [20, 21] and broadly targeted metabolomics [22–24] is a typical method to investigate suspected metabolic disorders and drug mechanisms nowadays. The sequencing of Microbial

diversity based on 16S rRNA is frequently used to detect changes in microbial-community diversity and species richness and can categorize bacteria rapidly and precisely. As a new “omics” field, metabolomics [25] possesses the characteristics of integrity, dynamicity, and non-targeting, and is a potent research tool for chronic metabolic diseases. It can reflect the metabolic pathways and networks of biological samples and identify metabolic anomalies at the molecular level that caused by disease. Typically, stool and serum are utilized as samples to examine changes in the variety of gut microbiota and metabolic differences before and after an experiment [26].

Consequently, the purpose of this study is to detect changes in intestinal flora using 16S rRNA sequencing when drugs induce intestinal flora disorder in mice. Our objectives were to conduct serum metabolomics investigations centered on metabolites, evaluate the effect of *A. lancea* extract on intestinal-microbiota problem, and analyze its therapeutic mechanism in mice based on alterations in endogenous chemicals [27].

Experimental materials

Experimental animals

We obtained a total of 18 healthy specific-pathogen-free (SPF) mice from Chengdu Dashuo Animal Co. Ltd. (Chengdu, China). The weight varied between 17.0 and 22.0 g.

Experimental drugs and reagents

A. lancea (with 0.30% atractyadin) was bought from Chengdu Durst Biotechnology Co., Ltd. (Chengdu, China). Cefradine capsules were bought from Hunan Kelun Pharmaceutical Co., Ltd. (Chengguan Town, China; State Food and Drug Administration (SFDA) Approval No. H43022215; specification: 0.5 g). Gentamicin sulfate was purchased from Huazhong Pharma Co., Ltd. (Shenzhen, China, SFDA Approval No. H42021503; specification: 2 ml: 0.08 g (80,000 units)). E.Z.N.A. Soil Kit (Omega Bio-tek, Inc., Norcross, GA, USA).

Experimental equipment

Thermo Cyclist PCR Analysis System (GeneAm9700) was purchased from Affinity Biosciences, Inc. (Cincinnati, OH, USA). The AxyPrep Deoxyribonucleic Acid (DNA) Gel Extraction Kit was purchased from Axygen Biosciences (Union City, CA, USA). The QuantiFluor-ST Double-stranded DNA (dsDNA) System was purchased from Promega Corp. (Fitchburg, WI, USA). An ultra-low-temperature freezer was purchased from Thermo Fisher Scientific (No. FUMA-86C). Liquid chromatography–mass spectrometry (LC–MS) methanol was purchased from Thermo Fisher Scientific (Moscow, Russia; Cat. No. A456-4). LC–MS acetonitrile was purchased from Thermo Fisher Scientific (Moscow, Russia; Cat. No. A955-4). LC–MS formic acid was purchased from Thermo Fisher Scientific (Moscow, Russia; Cat. No. A117-50). LC–MS water was purchased from Thermo Fisher Scientific (Moscow, Russia; Cat. No. W6-4). High-performance liquid chromatography (HPLC) 2-propanol was purchased from Thermo Fisher Scientific (Moscow, Russia; Cat. No. A451-4), NanoDrop2000.

Experimental method

Grouping and numbering of mice, and preparation of intestinal-dysbiosis mouse model

The mice were domesticated for 3 days before being randomly separated into three groups: C (normal saline), M (antibiotic: cefradine + gentamicin), and T (cefradine + gentamicin + *A. lancea*). They were designated by the designations C1–C6, M1–M6, and T1–T6. For modeling, each mouse in Groups M and T was administered 0.02 ml/g1/D1 of cefradine + gentamicin sulfate by intragastric (i.g.) gavage for seven days. Group C received an equivalent volume of normal saline by i.g. gavage for 7 days. At the end of the experiment, we collected mouse feces and preserved by freezing them in a cryogenic refrigerator. Figure 1 shows the experimental process.

Drug treatment

Group T mice were given *A. lancea* extract (0.02 ml/g⁻¹/D⁻¹) by i.g. gavage for 7 days, while Groups M and C were given normal saline.

Sample collection

Feces

Mouse feces from the last 3 days of the experiment were collected and stored in a sterile Eppendorf tube at –80 °C.

Serum

On the final day of the experiment, we used the lavage needle to collect blood from the mice's abdominal

cavities. The blood was kept on ice for 30 min and then centrifuged at 4 °C and 3000 g for 15 min. Afterwards, we extracted the supernatant (serum) and stored it in a freezer at –80 °C.

Treatment of fecal samples (16S rRNA diversity sequencing)

Deoxyribonucleic acid extraction and polymerase chain reaction amplification

DNA was extracted from the whole flora of the mouse feces following the instructions of an E.Z.N.A. Soil Kit. The concentration and purity of extracted DNA were determined using a NanoDrop 2000, and the DNA's quality was determined using 1% agarose gel electrophoresis. We amplified the V3–V4 variable region by polymerase chain reaction (PCR) using 806R and 338F primers.

Diversity sequencing

PCR products were extracted from 2% agarose gel, purified, analyzed, and quantified using the QuantiFluor-ST. The purified amplified sequences were made into a 2 × 300 paired-end (PE) library using an Illumina MiSeq platform and sequenced on a MiSeq PE300 platform.

Treatment of serum samples

Pretreatment

We moved 100 µL of plasma sample with precision and added 20 µL of internal standards (0.3 mg/ml L-2-chlorophenylalanine + acetonitrile). Subsequently, we added 400 µL extract (methanol:acetonitrile = 1:1) to the sample, mixed it in a vortex mixer for 30 s, and performed low-temperature ultrasonic extraction for 30 min at 5 °C and 40 kHz. Then, the sample was frozen at –20 °C for 30 min and centrifuged for 15 min (13,000 g, 4 °C), then the supernatant liquid was removed and blown dry with nitrogen gas. Finally, 100 µL complex solution (acetonitrile:water = 1:1) underwent low-temperature ultrasonic extraction for 5 min (5 °C, 40 kHz) and then centrifugation for 5 min (13,000 g, 4 °C), after which the supernatant was transferred to the sample bottle for machine detection.

LC–MS detection

The instrument used for LC–MS analysis was an AB SCIEX Ultra-HPLC (UHPLC) TripleTOF System.

Chromatographic conditions: The chromatography column was a BEH C₁₈; mobile phase A was water (containing 0.1% formic acid), while mobile phase B was acetonitrile: isopropanol (1:1; containing 0.1% formic acid). The flow rate was 0.40 ml/min, coupled with a 10 µL injection volume and a 40 °C column temperature.




Fig. 1 The experimental design and process

MS conditions: We used positive-ion and negative-ion scanning mode, as well as ion spray voltage for sample quality spectrum signal acquisition.

See Table 1 for specific parameters.

Data analysis

Intestinal-flora analysis

In the experiment, the original sequence from the MiSeq PE300 was checked for quality (QC) with Trimmomatic. Fast Length Adjustment of SHort Reads (FLASH) (Magoč and Salzberg, 2011) was used to optimize and screen bacterial 16S rRNA data. The experiment began by setting a 50-bp window. When average quality was < 20, all sequence fragments at the back end of the base were removed from the front of the window, and then sequence fragments < 50 bp long after QC

were removed. The experiment spliced two sequences based on overlap (maximum error matching rate = 0.2; length > 10 bp). According to the barcode and primers at the beginning and end of the sequence, we split the sequence for each sample. Finally, UPARSE (Edgar, 2013) was used to perform an operational taxonomic-unit (OTU) clustering analysis on the sequence based on 97% similarity.

Serum metabolite analysis

The data were initially preprocessed. We imported the raw data into the metabolomics processing software Progenesis QI (Waters) for baseline filtering, peak recognition, integration, retention time correction, and peak alignment. Ultimately, a data matrix containing retention time, mass charge ratio, and peak strength was acquired. Next,

Table 1 Source gas parameters and impact energy of mass spectrometry

Mass range	m/z	Parameter
Spray gas	Ion source gas 1 (psi)	50
Auxiliary heating	Ion source gas 2 (psi)	50
Gas curtain	Curtain gas (psi)	30
Heating temperature source	Source temperature (°C)	500
Ionization voltage (+)	Ion spray voltage floating (electrospray ionization [ESI] ⁺)(V)	+ 5000
Ionization voltage (-)	Ion spray voltage floating (ESI ⁻)(V)	- 4000
Voltage clustering	Declustering potential (V)	80
Impact energy	MS-MS collision energy (V)	20-60 (rolling)

the accompanying operations were performed: (1) retaining >80% of nonzero variables in the sample; (2) supplementing the minimum value missing from the original matrix; (3) normalizing the total peak; and (4) obtaining the data matrix via log transformation for further analysis. Then, we performed unsupervised principal component analysis (PCA) and supervised orthogonal partial least squares discriminant analysis (OPLS-DA). Student's *t* test and variable importance in projection (VIP) were coupled to identify differential metabolites, followed by differential-metabolite cluster analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional pathway, pathway enrichment, and topological analyses. The biological data of several metabolites were extracted.

Experimental results

Intestinal-flora analysis

The observed species (Sobs) index can be used to judge the richness of microbial colonies, while the Shannon index can be used to judge the diversity of such colonies. The number of microorganisms in the large intestines of mice that were gaged with normal saline is what "Group C" means. After the gavage of antibiotics, the diversity of organisms was greatest in Group M. As can be seen, compared with Group C, the species diversity and richness of the intestinal microbial community in Group M were lower. The T group reveals that specific bacteria exhibited a pattern of recovery and expansion (Figs. 2 and 3). After administration of *A. lancea*




Fig. 2 Diversity index. The abscissa is the sample, and the ordinate is the number of species observed at the genus level




Fig. 3 Student's *t* test histogram of intergroup differences. The abscissa is the group name, and the ordinate is the mean value of Shannon index at the OUT classification level. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$)

extract, the diversity and abundance of microorganisms in the large intestines of mice tended to recover and grow.

The bar diagram in Fig. 4 indicates the compositions of numerous phyla at various taxonomic levels, as well as the corresponding dominant phyla and their

proportions. At the phylum level, the biggest proportion of bacteria among the three groups was Firmicutes. The proportion of Bacteroides reduced considerably after antibiotic gavage, and Proteobacteria replaced it as the dominating phylum. Following treatment with *A. lancea* extract, Bacteroides and Actinomycetes proportions




Fig. 4 Histogram of sample community composition. The abscissa is the proportion of species, and the ordinate is the sample number

increased. When antibiotics were administered to mice, the phyla of bacterial in their intestines changed. The percentage of probiotics decreased. The equilibrium of flora was upset, and the usual growth of helpful beneficial bacteria was impeded. However, after treatment with *A. lancea* extract, the number of beneficial bacteria began to recover, and the proportion of harmful bacteria tended to return to its level prior to antibiotic administration, indicating that *A. lancea* extract had a

significant effect on restoring the balance of intestinal flora in mice.

For heatmap analysis, the 50 genera with the highest abundance were screened. The genera *Polyformis*, *Prevosiella*, and *Muribaculaceae* were more abundant in the normal group, as depicted by the community heatmap at the genus level (Fig. 5). Antibiotics decreased the number of bacteria in the normal group, but *Pseudomonas aeruginosa*, *Enterococcus*, and *Clostridium* increased in




Fig. 5 Heatmap of sample community. The abscissa is the sample number, the ordinate is the species name, and the legend is the species abundance value

number. The leading colonies were *Escherichia Shigella* and *Otherbacter*, and several of the more abundant communities in the normal group were recovering. However, the abundance of some medications was lower than that of antibiotics (Group A), which may have been due to the brief time of oral *A. lancea* extract administration and the ease with which other microorganisms were recovered from the environment formed by *A. lancea*. In contrast, several bacteria were more sensitive to the environment generated by antibiotics or *A. lancea*.

We utilized a Circos diagram (Fig. 6) to examine the composite proportions of dominant phyla in various samples. Under normal conditions, Firmicutes and Bacteroidetes are the dominant groups. In mice treated with antibiotics, Proteobacteria grew from 3.8% to 32%,

whereas Bacteroidetes declined from 43% to 5.5%, demonstrating that antibiotics can alter the composition of the intestinal flora and hence produce an intestinal-flora problem. After i.g. treatment with *A. lancea* extract, Mycorrhizae and Bacteroidetes were once again in the dominating floras. The drop in Proteobacteria and significant rise in Bacteroidetes (from 5.5% to 13%) demonstrated that *A. lancea* extract might enhance the number of beneficial bacteria in the digestive tract and restore the balance of intestinal flora.

We used the Kruskal–Wallis *H* test (Fig. 7) to assess statistically differences between groups and to determine differences in species richness within each group. As shown in Fig. 7, the three groupings included *Muribaculaceae*, *Clostridium*, *Lactobacillus*, *Prevotella*




Fig. 6 Circos diagram. In the Circos sample and species diagram, the large semicircle (right half circle) represents the distribution proportion of a species in different samples under a certain classification level (outer ribbon: species, inner ribbon color: different groups), and the length represents the specific distribution proportion; The small semicircle (left half circle) represents the composition of different species in a sample (outer band: grouping, inner band: species), and the relative abundance specific to length




Fig. 7 Multi-group comparison of significant differences between groups. The left column shows the species name under the genus classification, and the corresponding column shows the average relative abundance of the species in each sample group. Different groups have different colors. The right-hand side is the p -value. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$)

($P \leq 0.001$), *Eschia*, *P. aeruginosa*, *multiform rod-shaped bacteria*, and *Romboutsia* ($0.001 < P \leq 0.01$). There were significant differences between the eight different genera. In addition, the color columns of the three groups indicated that the species richness of Group C, which was initially low, increased after the administration of antibiotics. Examples include *P. aeruginosa* and *Clostridium*. These findings demonstrated that antibiotics can alter the equilibrium of intestinal flora. Following treatment with *A. lancea* extract, the relative abundance of these two species fell on average. These results demonstrated that *A. lancea* extract may restore the average relative abundance of intestinal microflora and treat intestinal dysbiosis in mice.

In addition, PCA based on OTUs indicated that these populations had distinct microbiome characteristics. As represented in Fig. 8, the results from the three groups showed a distinct difference phenomenon, confirming

the accuracy of our experimental methodology. At the same time, mouse A6 in Group A showed obvious separation from other members of the same group, which have been attributable to unique causes.

Significant separation was also observed in the hierarchical-clustering results (Fig. 9), which was consistent with PCA results. Meanwhile, the three classifications shown in Fig. 9 are unique, indicating that the test technique and grouping strategy we picked were appropriate. The performance of test objects in subgroups can be seen from the data set of Group C and Group A_A (Group T), but mouse A6 in Group A is clustered distant from the other members of the same group in the PCA graph due to its individual differences.

The abovementioned analytical results showed that the methodology utilized in our investigation was precise and efficient. In addition, they also proved that antibiotics threw mice's richness and diversity of intestinal flora




Fig. 8 Principal component analysis. The closer the two sample points are, the more similar the species composition of the two samples is




Fig. 9 Significance of differences between groups. Clustering tree graph for multi-group comparisons between samples

out of balance, resulting in intestinal-flora instability. The intestinal-flora structure of mice treated with *A. lancea* extract was considerably different from that of animals treated with antibiotics alone. Diversity and abundance of mouse intestinal flora tended to recover, as did the intestinal flora of mice not administered antibiotic injections. Using metabolomics, the impact and implications of these changes will continue to be examined and explored.

Serum metabolite analysis

Correlation heatmaps were obtained using Pearson's correlation coefficient (PCC) and Euclidean distance algorithms in both anionic and cationic modes (Fig. 10). As seen in Fig. 10 and Table 2, there were differences between Groups C and M, particularly in anionic mode. There were also changes between Groups C and T, but these were very minor in cationic mode, and differences were significant in anionic mode.




Fig. 10 Sample correlation heatmap. **A** Sample correlation heat map in C vs M positive ion mode; **B** Sample correlation heat map in C vs M negative ion mode; **C** Sample correlation heat map in C vs T cationic mode; **D** Sample correlation heat map in C vs T anionic mode

Table 2 Sample correlation coefficient table

Grouping	-		+	
	Average	SD	Average	SD
C vs. M	-0.21211	0.119361	-0.19895	0.148741
C vs. T	0.747097	0.042251	0.820833	0.044537

As shown in the PCA score chart (Fig. 11), we noticed a considerable separation between Group M and other groups in both cationic and anionic modes. In Fig. 11D, the PCA score chart of the T versus (vs.) M comparison group in cationic mode revealed a partial overlap between Groups T and M, probably because of two-dimensional nature of the exhibited images. Group M was separated from remaining groups.

In addition, additional OPLS-DA model analysis (Fig. 12) also indicated that Groups M and T were distinct, showing that *A. lancea* extract significantly changed the physiological-metabolic condition of mice following antibiotic therapy.

To verify the validity of the OPLS-DA model, we employed response permutation testing to assess its precision (Fig. 13). The main parameters were as follows: *Anionic mode*: R2X (cum)=0.612, R2Y (cum)=0.989, Q2 (cum)=0.827; *Cationic mode*: R2X (cum)=0.538, R2Y (cum)=0.994, Q2 (cum)=0.808. The above parameters are all more than 0.5, R2Y had a high value. This investigation produced a model with great precision, stability, and dependability.

Using a volcano map (Fig. 14), we were able to quickly determine the statistical significance of variations in metabolic-expression levels between antibiotics and *A. lancea* extract after gavage and the statistical significance thereof. Figure 14A/14C depicts a multitude of substantially up-regulated regions. Groups T and C differ significantly in up- and down-regulated regions (red and green, respectively) as depicted in Fig. 14C. However, because there is only one value in the red area beyond abscissa 4, this result may have been caused by previously indicated. In addition, the kind of bacteria after *Atractylodes* lavage was superior




Fig. 11 PCA score chart. **A** PCA score of comparison group M vs C in anionic mode; **B** PCA score of M vs C comparison group in cation mode; **C** PCA score of comparison group T vs M in anionic mode; **D** PCA score of T vs M comparison group in cation mode




Fig. 12 OPLS-DA score chart. **A** ops-da score of M vs T comparison group in anionic mode; **B** pls-da score of T vs M comparison group in cation mode




Fig. 13 Response permutation test chart. **A** Response permutation test in anion mode; **B** Response permutation test in cation mode




Fig. 14 Difference volcano map. **A** M vs C differential volcanic map; **B** T vs M differential volcanic map; **C** T vs C differential volcanic map

Table 3 Top 30 metabolites in Group M vs Group C: summary of differential metabolites in the control group

Name	m/z	VIP_pred	FC (M/C)	P
Hippuric acid	180.0642	3.2855	1.4692	0.00000001
3-Indolepropionic acid	190.085	4.8292	3.0467	0.00000003
Included acid M	463.3049	3.4779	2.6813	0.00000017
Ethyl maltol	105.0325	3.2351	1.6146	0.00000020
Deoxycholic acid	437.2911	3.4058	1.9847	0.00000032
Cefradine	348.1023	4.1577	0.5041	0.00000054
5-Oxygen-ferulic melanin	452.1549	4.0003	3.5866	0.00000104
Catechol sulfate	188.9862	4.0163	2.4593	0.00000148
Tetradecane diacid	281.1709	1.7161	1.1415	0.00000150
5C-glycoside ligand	273.1145	3.5433	1.8701	0.00000207
Cinnamyl glycine	206.0797	3.7539	2.1163	0.00000909
2-Phenylethanol glucosidic acid	297.098	3.7474	2.0734	0.00000991
Tetracycline	637.3469	1.7577	1.1475	0.00005165
Ganoderic acid H	607.2625	1.8047	1.3637	0.00007320
(±)12(13)-Epoxy oleic acid	295.2277	1.6249	1.0891	0.00008150
Lysophosphatidylethanolamine (0:0/22:0)	582.3798	1.599	0.9258	0.00009721
Lysophosphatidylethanolamine (0:0/22:1 [13Z])	580.3636	1.5418	0.9221	0.00012840
(E)-10-OXO-8-caproic acid	183.1024	1.6872	1.2462	0.00014960
(1)-(E)-13-hydroxy-10-OXO-11-octadecenoic acid	277.2152	1.7374	1.1127	0.00015680
Lysophosphatidylethanolamine (0:0/18:2 [9Z,12Z])	522.285	1.6841	0.8144	0.00017630
Phosphatidylcholine (19:1 [9Z]/0:0)	536.3709	1.5516	0.9395	0.00019640
Phosphatidylcholine (17:2 [9Z, 12Z]/0:0)	506.324	1.1043	0.9605	0.00020110
13S-ambrettolic acid	341.2337	2.185	1.3138	0.00021100
Theophylline	649.2492	2.1059	0.7866	0.00032180
Squalane	275.2009	2.2094	1.6423	0.00032480
(±)12,13-Dihydroxy octadecenoic acid	313.2384	1.5145	1.0802	0.00034500
Lysophosphatidylcholine (20:1 [11Z])	594.3798	1.1581	0.9562	0.00039740
Citric acid	191.0198	1.4411	1.091	0.00047770
(S)-5-Hydroxyl-eicosatetraenoic acid-(Hete)	321.2435	1.5976	1.1383	0.00052270
Pc (22:6 [4z, 7z, 10z, 13z, 16z, 19z]/16:1 [9z])	848.5504	1.4852	0.927	0.00053100

to that after antibiotic lavage, and the number of beneficial bacteria was inconsistent with that before lavage. The majority of strongly upregulated and downregulated regions fall within the range of abscissa 1 to 2, with significantly upregulated regions comprising a higher proportion.

The top 30 significantly differential metabolites in the comparison groups (C vs. M and M vs. T; Tables 3 and 4) was identified using a screening condition of $P < 0.05$, $VIP_pred_oPLS-DA > 1$, fold change $[FC] > 1$, or $FC < 1$. Compared to Group C, the contents of phospholipids such as cephradine, theophylline, lysophosphatidylcholine (LysoPC), and lysophosphatidylethanolamine in Group M were significantly decreased, while the concentrations of 2-phenylglycolic acid, cinnamyl glycine, catechol sulfate, gibanolic acid M, 3-indolepropionic acid, and 5-oxy-ferulic melanin in Group M were significantly

increased. Compared to Group M, lipids such as phosphatidylcholine and terpinyl anthranilate were increased in Group T, but emodin, hydroxyl hexadecarboxylic acid, 3-carboxylic 2,3,4,9-tetrahydro1h-pyridine [3,4-B] indole-1-propionic acid, daidzein, and 2-hydroxyundecanoic acid were significantly decreased, indicating that metabolites were significantly changed after antibiotic treatment. *A. lancea* extract in moderation and the number of beneficial bacteria gradually recovered after i.g. administration.

The cluster analysis of the first thirty metabolites is depicted in Fig. 15. As shown, the expression levels of LysoPC, lysophosphatidylethanolamine, arachidonic acid (AA), and other substances were significantly altered after treatment. The number of metabolites annotated to the lipid metabolism pathway was the greatest, followed by those annotated to the amino acid metabolism

Table 4 Top 30 metabolites in Group T vs Group M: summary of differential metabolites in the control group

Name	m/z	VIP_pred	FC (T/M)	P
RMB 5 c glycosides	273.115	2.7522	0.6965	0.000000018
Rheum emodin	269.045	3.2115	0.3121	0.000000369
DL-2-aminocaprylic acid	160.132	2.4555	1.3267	0.000012090
Malarate	276.199	2.5836	1.3973	0.000046840
(R)-8-acetoxy coumarin acetone	211.132	2.0582	1.2038	0.000053490
5,9-Table dioxane-3-hydroxyergosteride-7-alkene-6-ketone	443.317	2.7401	1.8409	0.000057530
Morindone Q	643.231	3.0719	3.1994	0.000061970
2-E thiophene	199.097	1.8265	1.3509	0.000063960
Hydroxy hexadecarbonate	301.201	2.7644	0.4055	0.000070190
Ficoceryl alcohol	242.247	1.4816	0.909	0.000099410
Phosphatidylcholine (8Z, 11Z, 14Z, 17Z)	810.600	1.2751	1.0362	0.000104800
2,7(14)-Isoprene-10,15-diol	279.160	1.5489	1.1942	0.000150700
Decyl alcohol	200.200	1.432	0.9271	0.000166400
Daidzein	255.064	3.4924	0.4635	0.000230700
Terpinyl o-aminobenzoate	274.182	2.3973	1.2634	0.000295500
(±)12,13-Dyhydroxy-9z-octadecenoic acid	313.238	1.5429	0.9115	0.000309800
Pteroside Z	415.172	1.8806	0.6016	0.000310500
Dodecyl alcohol	228.231	1.3948	0.9332	0.000316300
(±)13-Octadecadienoic acid	295.226	1.7853	0.8774	0.000355500
Carboxyl-2,3,4,9-tetralin-1H-pyridine[3,4-b]benzpyrole-1-propionic acid	287.103	2.462	0.4059	0.000384700
Phosphatidylcholine (4Z, 7Z, 10Z, 13Z, 16Z, 19Z)	854.567	1.0789	1.035	0.000412900
Dihydrogen DNA-8-isoamyl alcohol	255.121	2.3496	1.5766	0.000417700
Phosphatidylcholine (7Z, 10Z, 13Z, 16Z)	854.597	1.2123	1.0562	0.000422300
1,17-Heptandiol	314.305	1.4145	0.9137	0.000477900
5(s)-Hete hydroxyl-eicosatetraenoic acid (HETE)	321.243	1.3721	0.8896	0.000499600
Glycoprotein	285.074	2.5292	0.5913	0.000579500
Benzoquinone acetic acid	165.019	2.3902	1.7328	0.000583800
(R)-3-hydroxybutyrate carnitine	248.148	2.2202	1.2947	0.000592300
2-Hydroxyundecanoic acid	201.149	1.9738	0.5553	0.000595400
Baicalin	447.091	2.5655	0.6928	0.000660800

pathway (Fig. 16). Differentially annotated lipid metabolites comprise AA, taurocholic acid, traumatic acid, palmityl l-carnitine, dodecanedioic acid, 21-deoxycortisol, 3-oxygen-sulfolactose ceramide, 17-hydroxyprogesterone, 13S-hydroxyoctadecenoic acid, phosphatidylcholine (24:1 [15Z]), phosphatidylcholine (18:3 [6Z, 9Z, 12Z]), and phosphatidylcholine (16:0). The amino acid metabolic pathway were such differential metabolites as phenylacetyl glycine, L-methionine, indoleacetaldehyde, thyroxine, gin, and m-coumaric acid.

Figure 17 depicts the KEGG enrichment analysis of differential metabolites as a diagram of bubbles. As shown in the enrichment analysis bubble diagram of Group M vs Group C, the bubbles in the bile secretion pathway are the greatest, as was the number of metabolites enriched to metabolic concentration (4). The second pathway was phenylalanine metabolism, which

was enriched with three metabolites. Two metabolites were enriched for the linoleic acid metabolism, the α -linolenic acid metabolism, the glycerol phospholipid metabolism, the mutual conversion of pentose and glucuronic acid, the arginine metabolism, and the proline metabolism. As seen in the enrichment analysis bubble diagram for Group T vs. Group M, the bubbles in linoleic acid metabolism, phenylalanine metabolism, tryptophan metabolism, steroid biosynthesis, bile secretion, ovarian-steroid production, and other pathways are the largest and identical in size, indicating that the number of metabolites enriched to metabolic concentration was equivalent. The ovarian-steroid route has the highest degree of enrichment, followed by linoleic acid metabolism.

According to the KEGG topology analysis bubble diagram of differential metabolites (Fig. 18), the most




Fig. 15 Group M vs Group C cluster analysis of the first 30 metabolites in the control group

important KEGG pathway was MAP00590, namely, the AA metabolism pathway. We used Interactive Pathways Explorer (iPath) v3.0 for visual examination of the metabolic pathways of all differential metabolites (Fig. 19). As shown in Fig. 18, lipid metabolism and amino acid metabolism accounted for the majority.

Correlation analysis between intestinal flora and serum metabolomics

To determine the potential relationship between changes in intestinal flora in feces and changes in metabolites in serum from mice, we compared three conditions and analyzed correlations between differential metabolites




Fig. 16 KEGG pathway charts. **A** Group M vs Group C; **B** Group T vs Group M




Fig. 17 KEGG enrichment analysis. **A** Group M vs Group C; **B** Group T vs Group M

in serum and intestinal microflora using Spearman's correlation coefficient (SCC). Figure 20A shows that *G_Odoribacter*, *G_Gordonibacter*, and *Helicobacter* were positively correlated with phenylacetyl glycine,

lentialexin, and LysoPC. *Staphylococcaceae* and *Streptococcaceae* were positively correlated with phenyluronic acid, lentialexin, and LysoPC, as depicted in Fig. 20B. *Helicobacteraceae* showed a positive correlation with the




Fig. 18 KEGG topology analysis. **A** KEGG Topology Analysis of M vs C; **B** KEGG Topology Analysis of T vs M

A group. In the C group, *Odoribacter* was positively correlated with phenylacetyl glycine, lentialexin, and LysoPC, just as it was in the A group. *G_Ruminococcaceae* was also positively correlated with these three metabolites, as well as with other species of *G_Ruminococcaceae*. As depicted in Fig. 20, the connection between bacterial species and metabolites in the three groups was broadly comparable, however species differences led to variances in the final results. As a result, we hypothesized that this link was highly dependable and that the metabolites in question could be those of these species or derivatives thereof.

Conclusions

A. lancea is a commonly used TCM in treating GI diseases for its great effect of “clearing dampness”. With the deepening of modern pharmacological researches, increasing researches have demonstrated that *A. lancea* shows a certain effect in alleviating intestinal diseases. For example, it could reduce DSS-induced colitis by regulating intestinal flora and metabolites [29], as well as relieving constipation by regulating intestinal flora [30]. It is clear that intestinal flora plays a crucial role in resulting in GI diseases. What’s more, the components in serum are supposed to affect the types and numbers of intestinal flora [31]. And it is feasible to affect the types and numbers of intestinal flora by using natural products to alleviate or treat diseases [32]. Therefore, in this study, we

focus on the intestinal flora and metabolites to study the therapeutic effect of *A. lancea* on GI diseases and explore its underlying mechanisms.

In this study, based on gene sequences of microbiota in the feces of three experimental mouse groups that received different treatments intragastrically, we used 16 s rRNA gene sequencing to detect changes in intestinal microbes and to study whether the extract of the Chinese herbal medicine *A. lancea* had effects on the intestinal flora. The results indicated that when mice were treated with antibiotics (gentamicin and cefradine), their gut flora became less diverse. The dominant species composition of their intestinal flora changed from beneficial to harmful bacteria, and the proportion of Proteobacteria increased. The mice displayed diluted feces, lower activity levels, and rougher hair. By the conclusion of the modeling period, when the mice were administered with *A. lancea* extract, the species composition of their intestinal flora began to restore to normal proportions. Bacteroides and Mycorrhizae colony proportions increased, and microbial equilibrium was restored. The mouse’s hair grew silky once more. Normal feces were observed, and their activity level increased.

Based on the results of our metabolomics analysis, we determined that *A. lancea* extract had a significant effect on the lipid and amino acid metabolism of mice. Lipid metabolism is likely reflected in AA metabolism, and amino acid metabolism is most likely reflected in




Fig. 19 iPath metabolic pathway. **A** iPath metabolic pathway T vs M; **B** iPath metabolic pathway M vs C; **C** iPath metabolic pathway of T vs C




Fig. 20 Spearman's correlation coefficient. **A** M is associated with the C analysis, **B** T is associated with the C analysis, and **C** T is associated with the M analysis

L-methionine metabolism. Lipids, the energy suppliers for organisms, participate in a variety of vital processes, including including the maintenance of cell membrane structure, energy storage, and signal transduction and transport. Linoleic acid is an essential fatty acid that cannot be synthesized by the body and so must be consumed. According to studies, cholesterol in the body can only operate normally when paired with linoleic acid; in the absence of linoleic acid, cholesterol can cause metabolic abnormalities. AA is a ω -6 polyunsaturated fatty acid and a linoleic acid metabolite. Being a chemical with significant biological activity, it plays a critical part in the inflammatory metabolic process. Under conditions of oxidative stress, the conversion of linoleic acid to AA is accelerated. Most inflammatory mediators are created by the metabolism of AA [28]. The cyclooxygenase (COX) and lipo-oxygenase (LO) metabolic pathways can convert

AA to prostaglandins (PGs). Inflammation is linked to PGs, prostacyclin (PGI1), thromboxane (TX), and leukotrienes (LT).

Our experimental findings demonstrated that *A. lancea* extract may restore normal levels of possible biomarkers in mice, including hemolysis phosphatidyl choline, L-glutamic acid, AA, deoxycholic acid, and bile acid. The normalization of the index indicates that the intestines of mice eventually recover from metabolic abnormalities. In addition, this extract could be used to treat antibiotic-induced metabolic abnormalities in mice. The mechanism of action may involve the metabolism of AA and phospholipids to increase the level of prostaglandin E2 (PGE2) in the stomach, thereby inhibiting gastric acid output, improving ulcers, and exerting immunosuppressive and anti-inflammatory actions. With the alleviation of the mice's diarrhea, the serum metabolite

levels returned to normal. This partially explained the therapeutic impact of *A. lancea* extract and reflected the related changes in the body's microscopic and macroscopic states during medication therapy. According to the enrichment bubble diagram, the elevated serum fatty acid and amino acid levels of mice in the treatment group suggest that these two metabolic pathways were more active, as was the bile secretion route.

In this study, we effectively developed a mouse model of intestinal-microflora problem induced by antibiotics, and then used 16S rRNA gene sequencing and metabolomics to analyze the regulation mechanism of *A. lancea* extract on this condition. In these trials, we discovered that *A. lancea* extracts may partially restore the gut microbiota, the primary and secondary biliary lipid metabolism, and the amino acid metabolism pathways, as well as reverse metabolic abnormalities caused by antibiotic therapy. We believe that this study will provide new medicinal concepts for advancing our understanding of the pathophysiology of intestinal inflammation and the early detection of intestinal microbiota imbalance.

Authors' contributions

TH and YZQ conceived the original idea of the project. ZBN, TJ, and ZMH carried out the experiment. ZBN, BL, ZYY and WQ participated in the manuscript preparation. TCJ, FDR and XZP participated in the design of the study and supervised. All authors read and approved the final manuscript.

Funding

This study was supported by National Natural Science Foundation of China (Number: 81202933), Natural Science Foundation of Sichuan Province (Number: 2022NSFSC0592), Science and Technology Plan Project of Mianyang City (Number: 2018YFZJ025).

Declarations

Competing interests

The authors declare no competing interests.

Author details

¹Key Laboratory of Quality Control of Traditional Chinese Medicine in Northwest Sichuan, Mianyang Normal University, Mianyang 621000, China. ²Mianyang Institute for Food and Drug Control, Mianyang 621000, China. ³Beichuan Shennong Agriculture Technology Development Co., Ltd, Mianyang 621000, China.

Received: 15 February 2023 Accepted: 3 April 2023

Published online: 15 April 2023

References

- Kim JH, Jeon JY, Na H, Kim JK, Moon SJ, Kim MG. Long-term taxonomic and functional stability of the gut microbiome from human fecal samples. *Sci Rep*. 2023;13(1):114.
- Sun XF, Pan BH, Sun DY. Research progress on the correlation between intestinal microbiota and host metabolic function. *Feed Res*. 2014;1:37–8+73.
- Bounous G, Ghislain DJ. Effects of an elemental diet on human fecal flora. *Gastroenterology*. 1974;66:210–4.
- Schneider SM. Microbiota and enteral nutrition. *Gastroenterol Clin Biol*. 2010;34:S57–61.
- Loeschke K. Antibiotika-assoziierte diarrhoe and enterocolitis. *Klin Wochenschr*. 1980;58:337–45.
- Toffler RB, Pingoud EG, Burrell MI. Acute colitis related to penicillin and penicillin derivatives. *Lancet*. 1978;2(8092 Pt 1):707–9.
- Youn Y, Lee SW, Cho HH, Park S, Chung HS, Seo JW. Antibiotics-associated hemorrhagic colitis caused by *Klebsiella oxytoca*: two case reports. *Pediatr Gastroenterol Hepatol Nutr*. 2018;21(2):141–6.
- Akanbi O, Saleem N, Soliman M, Pannu BS. Antibiotic-associated hemorrhagic colitis: not always *Clostridium difficile*. *BMJ Case Rep*. 2017;2017:bcr2017219915.
- Zhao WH, Du WX. Research progress on the interaction between effective components of traditional Chinese medicine and intestinal flora. *Proceed Inter Dig Med Soc Dig Tradit Chin Med*. 2017;2017:659–60.
- Chinese Pharmacopoeia Commission. *Pharmacopoeia of the People's Republic of China*. Beijing: China Medical Science and Technology Press. 2015(6).
- Xie J, Peng F, Yu L, Peng C. Pharmacological effects of medicinal components of *Atractylodes lancea* (Thunb.) DC. *Chin Med*. 2018;13:59.
- You SL, Li J, Yan T, Peng F, Liu S. Preventive effects of *Rhizoma Coptidis* and *Atractylodes* on mice with gastric-ulcer. *J Ctrl South Univ Med sci*. 2020;45(1):8–16.
- Yu Y, Jia TZ, Cai Q, Jiang N, Ma MY, Min DY, Yuan Y. Comparison of the anti-ulcer activity between the crude and bran-processed *Atractylodes lancea* in the rat model of gastric ulcer induced by acetic acid. *J Ethnopharmacol*. 2015;160:211–8.
- Wang KT, Chen LG, Wu CH, Chang CC, Wang CC. Gastroprotective activity of atractylenolide III from *Atractylodes ovata* on ethanol-induced gastric ulcer in vitro and in vivo. *J Pharm Pharmacol*. 2010;62(3):381–8.
- Sakurai T, Sugawara H, Saito K, Kano Y. Effects of the acetylene compound from *Atractylodes rhizome* on experimental gastric ulcers induced by active oxygen species. *Biol Pharm Bull*. 1994;17(10):1364–8.
- Bailey C. Atractylenolides, essential components of *Atractylodes*-based traditional herbal medicines: Antioxidant, anti-inflammatory and anticancer properties. *Eur J Pharmacol*. 2021;891: 173735.
- Dong HY, Shao JW, Wang T, Guo YH, Yan LY. Effects on the activities and mRNA expression of CYP3A in rat's liver by four kinds of extracts from anti-cancer Traditional Chinese Medicines. *J Chin Med Mater*. 2008;31(1):68–71.
- Wang R, Zhou G, Wang M, Peng Y, Li X. The metabolism of polysaccharide from *Atractylodes macrocephala* Koidz and its effect on intestinal microflora. *Evid Based Complement Alternat Med*. 2014;2014: 926381.
- Yang FJ. Planting methods and pharmacological effects of *Atractylodes atractylodes*. *Breeding Tech Cons*. 2013;211.
- Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, Glöckner FO. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. *Nucleic Acids Res*. 2013;41(1): e1.
- Hall M, Beiko RG. 16S rRNA Gene Analysis with QIIME2. *Methods Mol Biol*. 2018;1849:113–29.
- Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. *Curr Protoc Mol Biol*. 2012;30:Unit 30.2.1–24.
- Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted metabolomics strategies-challenges and emerging directions. *J Am Soc Mass Spectrom*. 2016;27(12):1897–905.
- Kumar A, Misra BB. Challenges and opportunities in cancer metabolomics. *Proteomics*. 2019;19(21–22): e1900042.
- Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica*. 1999;29(11):1181–9.
- Zhuang XX, Gao JR, Yang XX, Wei LB, Han YQ, Xia LZ. Application status of metabolomics in traditional Chinese medicine research of diabetes. *Chin J Tradit Chin Med Inform*. 2014;21(4):126–9.
- Liu CX. Effects of gut microbiota on health, disease, and drug action. *Chin J Antibiot*. 2018;43(1):1–14.
- Cai YW, Liu JH, Ma N. Research status of arachidonic acid-targeted metabolomics in inflammation. *Chin J Clin Pharmacol*. 2021;37(19):2721–3+2728.
- Qu LH, Liu CL, Ke C, Zhan X, Li LQ, Xu HY, Xu K, Liu YJ. *Atractylodes lancea* Rhizoma attenuates DSS-induced colitis by regulating intestinal flora and metabolites. *Am J Chin Med*. 2022;50(2):525–52.

30. Wang LF, Wang F, Zhang XF, Chen QY, Xu J, Li HT, Li FQ, Yang M. Transdermal administration of volatile oil from *Citrus aurantium-Rhizoma Atractylodis Macrocephalae* alleviates constipation in rats by altering host metabolome and intestinal microbiota composition. *Oxid Med Cell Longev.* 2022;2022:9965334.
31. Chen S, Gui R, Zhou XH, Zhang JH, Jiang HY, Liu HT, Fu YF. Combined microbiome and metabolome analysis reveals a novel interplay between intestinal flora and serum metabolites in lung cancer. *Front Cell Infect Microbiol.* 2022;12: 885093.
32. Li WD, Li LS, Yang FJ, Hu QY, Xiong DQ. Correlation between gut bacteria *Phascolarctobacterium* and exogenous metabolite α -linolenic acid in T2DM: a case-control study. *Ann Transl Med.* 2022;10(19):1056.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

